Skip to main content
. 2019 Nov 3;9(1):1683347. doi: 10.1080/2162402X.2019.1683347

Figure 5.

Figure 5.

Prognostic value of CD206 expression in the context of established risk stratification schemes. (a) OS and EFS according to CD206 expression levels among intermediate-risk patients from Cohort 3. (b) OS of CN-AML patients (Cohort 3) in the ELN Favorable (left) and ELN Intermediate-I (right) genetic groups, according to CD206 expression levels. (c and d) OS and EFS of patients from Cohort 2 (left) and from Cohort 3 (right) as stratified by the LI24 (c) and the LSC17 (d) signature. Patients with a low and high risk score were further dichotomized according to CD206 expression levels.